AMTB
CAY-25336-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
926023-82-7
Formulation
A solid
Purity
≥98%
MW
431
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8).{37683} It inhibits calcium influx induced by the TRPM8 agonist icilin (Item No. 10137) with an IC50 value of 0.58 µM. AMTB (3 mg/kg) decreases the number of volume-induced bladder contractions in a rat model of noxious bladder distension. It also decreases the visceromotor reflex response to urinary bladder distension (ID50 = 2.42 mg/kg), indicating antinociceptive activity. AMTB inhibits the sodium channel (Nav) isoforms Nav1.1-1.8 (IC50s = 2-14.8 µM) and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells (IC50s = ~23.7 and 17.3 µM, respectively) in a TRPM8-independent manner.{37684}
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
